SynthesisBMC oral health2026
Survival rate and risk factors of implants in patients with head and neck neoplasms: a systematic review and meta-analysis.
Synthesis in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this meta-analysis was to evaluate the survival rate of oral implants and investigate potential risk factors for implant therapy in HNN patients. MATERIALS AND
methodsAn extensive search was conducted in four electronic databases from their inception to April 2024. Study selection, data extraction, and risk of bias assessment were performed independently by two reviewers. Survival rates were calculated and analyzed using R software. Meta-analyses were performed using fixed-effects or random-effects models based on heterogeneity assessment (random-effects model used when I² > 50% and/or Q-test P < 0.10) to calculate the risk ratio (RR) for implant survival. although retrospectively registered in Prospective Register of Systematic Reviews (PROSPERO), the study protocol was developed prior to data synthesis and adhered to the PRISMA guidelines.
resultsForty-two studies (2,448 patients, 10,164 implants) with heterogeneous follow-up durations (range: 1-12 years) were included. The pooled aggregate implant survival rate was 88% (95% CI: 85-90%), derived from single-arm analyses and representing crude survival proportions rather than time-specific estimates. Significant heterogeneity was observed among studies (I² = 94.9%; P < 0.0001). The meta-analyses revealed the following results: (1) Implant survival was significantly lower in irradiated bone compared to non-irradiated bone (18 studies, RR for survival = 0.95; 95% CI = 0.91-0.99; P = 0.03). (2) Implant survival was significantly lower in grafted bone compared to native bone (15 studies, RR for survival = 0.92; 95% CI = 0.88-0.97; P = 0.0008). (3) implant survival rates were significantly higher in patients who underwent hyperbaric oxygen therapy (HBO) compared to those who did not (5 studies, RR for survival = 1.47; 95% CI = 1.06-2.03; P = 0.02). (4) implants placed in the anterior region had significantly higher survival compared to those in the posterior region (6 studies, RR for survival = 1.07; 95% CI = 1.02-1.12; P = 0.008).
conclusionThe aggregated evidence suggests an overall implant survival rate of 88% (95% CI: 85-90%), though with substantial heterogeneity (I² = 94.9%). Radiation therapy and bone grafting were associated with statistically significant but modest reductions in implant survival. Conversely, implant placement in the anterior region and adjunctive HBO showed potential survival benefits. HBO showed potential benefit (RR = 1.47), but this finding was based on only five studies with considerable heterogeneity (I² = 91%) and requires confirmation in larger and randomized trials.
trial registrationThe investigation was retrospectively registered in the International PROSPERO under the application identifier CRD42024604320.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.